Replies to post #4159 on Biotech Values

[fitenough]

Based on cash on hand it would seem ALN compared to PFE would have a more difficult tme meeting the financial test of a lucrative partnership with GENR, as it looks like EYET might have similar problems that ALN has had. Sure has the makings of a bidding war.